Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody

Simona Cignetto(Candiolo Cancer Institute), Elisa Vigna(Candiolo Cancer Institute)
Molecular Oncology
March 28, 2016
10.1016/j.molonc.2016.03.004
Cited by 14

Related Papers

Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
|Journal of Biological Chemistry|2010|77
A receptor-antibody hybrid hampering MET-driven metastatic spread
|Journal of Experimental & Clinical Cancer Research|2021|11
Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
|Cancers|2020|3
Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination
|Cancers|2023|1